Clinical Trial Update: RE104 Safety and Efficacy Study in Generalized Anxiety Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial RE104 for generalized anxiety disorder is listed as not yet recruiting, evaluating safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• RE104

Snippet

Sponsor: Reunion Neuroscience Inc | Conditions: Generalized Anxiety Disorder | Phase 2 | Status: NOT_YET_RECRUITING